Prof. Dr. Dr. Klaus Strein is co-founder of the LamKap Bio group where he serves as executive Chairman of the Board.
He was with Roche from 1998 to 2011, during which time he held various responsibilities, including head of pharma research activities in Germany, head of therapeutic protein initiative and head of global pharma research. From 1979 to 1998 Klaus served in various positions at Boehringer Mannheim, including head of Pharma R&D. At that time, he was involved in the R&D of medicines like ibandronate (osteoporosis and metastatic bone disease), carvedilol and reteplase (cardiovascular diseases) and clinical development of erythropoietin in cancer.
Since 2012 Klaus is engaged in the Biotech Industry. From 2013 to 2020 he was a member of the Board of BB Biotech AG. In 2013 he co-founded EngMab AG which was focused on the R&D of T cell bispecific antibodies and has been acquired 2016 by Celgene. He is also a member of the Board of NovImmune/Light Chain Bioscience.
He holds post-graduate degrees in chemistry and medicine from the University of Heidelberg, where he was also appointed Adjunct Professor.
